Alameda, CA.—(BUSINESS WIRE)—February 12, 2007—Advanced Cell Technology, Inc.’s (OTCBB: ACTC) Michael West Ph.D., President and Chief Scientific Officer highlighted the Company’s ACTCellerate Platform, yesterday, at the 2nd Annual Stem Cell Summit, in San Diego. While the Company’s core focus is advancing its therapies related to the eye, vascular system, and skin, the Company believes this platform could augment the potential product applications from what many believe to be the most powerful cell, the human embryonic stem cell.
Human embryonic stem cells (hESC) are the first cells cultured in the laboratory capable of becoming every cell type in the human body. Therefore, the emerging field of regenerative medicine holds great promise for the treatment of many currently untreatable diseases. Despite that potential, researchers have not previously demonstrated efficient means of producing a large array of therapeutically-useful cell types in a pure and scalable form that allows them to be tested for potential human therapeutic use. The Company’s proprietary ACTCellerate platform was invented by the Company as a means of accelerating the differentiation of cells from human embryonic stem cells, thereby expanding potential products made from embryonic stem cell technology.
Dr. West’s presentation will be available for viewing at the Company’s web site www.advancedcell.com/conference-presentations/.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit www.advancedcell.com.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
The Investor Relations Group
Investors: James Carbonara, 212-825-3210
Media: Bill Douglass, 212-825-3210
Source: Advanced Cell Technology, Inc.
James Carbonara
212-825-3210